An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

•GSK3052230 is a novel FGF ligand trap with a unique mechanism of action.•GSK3052230 avoids on-target toxicities observed with small molecule FGFR inhibitors.•GSK3052230 combined with standard of care chemotherapy in sqNSCLC is well tolerated.•Combo responses were higher compared to historical chemo data in first line sqNSCLC.•A randomized trial would be necessary to determine the benefits of GSK3052230.